Advanced

AJNR - American Journal of Neuroradiology

This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Rohde, S. Articles by Berkefeld, J. Search for Related Content PubMed PubMed Citation Articles by Rohde, S. Articles by Berkefeld, J.

American Journal of Neuroradiology 26:1804-1809, August 2005
© 2005 American Society of Neuroradiology

INTERVENTIONAL

Intra-Arterial High-Dose Chemotherapy with Cisplatin as Part of a Palliative Treatment Concept in Oral Cancer

S. Rohde^a, A. F. Kovács^b, B. Turowski^a, B. Yan^a, F. Zanella^a and J. Berkefeld^a

^a Institute of Neuroradiology, Johann Wolfgang Goethe-University Medical School, Frankfurt am Main, Germany
^b Department of Maxillofacial Surgery, Johann Wolfgang Goethe-University Medical School, Frankfurt am Main, Germany

Address correspondence to Stefan Rohde, MD, Department of Neuroradiology, University of Heidelberg, Im Neuenheimer Feld 110, 69120 Heidelberg, Germany

BACKGROUND AND PURPOSE: Patients with cancer of the oral cavity often present with advanced tumor stages, distant metastasis, or severe comorbidities, which render radical surgery infeasible. The purpose of this study was to investigate the response rate, technical feasibility, and safety of intra-arterial (IA) chemotherapy as palliative treatment in this situation.

METHODS: From November 1997 to December 2003, 64 patients with histologically proven oral squamous cell carcinoma, classified as inoperable, received IA high-dose chemotherapy with cisplatin as a palliative treatment at our institution. To minimize toxic side effects, sodium thiosulfat was given intravenously.

Twenty-eight percent of the patients were female; average age was 61.5 years. Clinical staging of primary tumors was TNM (tumor, nodules, metastases) stage IV in 89%, stage III in 6.3% and stage II in 4.7%. After local chemotherapy, additional radiation of the tumor area or radiochemotherapy was performed in 33 patients.

RESULTS: There were no major catheter-related complications or severe side effects of IA chemotherapy. After the first cycle, 10% percent of the patients had complete remission (CR), 35% had partial response (PR), and 43.3% presented with stable disease.

Mean follow-up interval was 11 ± 12.9 months. Forty-five patients died after a mean period of 7.6 ± 7.0 months (median, 5.1 months). The overall 1- and 2-year survival rates were 29.5% and 18%, respectively. There was a trend toward longer survival in patients who received subsequent radiation or radiochemotherapy after IA chemotherapy.

CONCLUSION: IA chemotherapy in patients with inoperable carcinoma of the oral cavity as palliative treatment was technically feasible and safe. The overall response rate after IA chemotherapy was 45% (CR 10%; PR 35%). Side effects could be minimized by neutralizing the cytotoxic agent by sodium thiosulfat.